Medical Devices

With a $30M+ boost and a public market debut, Ionetix aims to scale its cyclotron tech for cancer therapy, diagnostics, and future energy solutions.

A breakthrough study in a Nature journal reveals a novel device, RefluxStop, has a stellar long-term safety record, offering hope for millions with severe GERD.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

A new app for the MyoPro robotic arm empowers patients and gives clinicians powerful data, marking a new step in connected assistive technology.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Atsena Therapeutics gets the green light for the final trial phase of a promising gene therapy, offering the first real hope for patients with X-linked retinoschisis.

A new partnership will embed sensors in spinal implants, aiming to solve high patient dissatisfaction rates and disrupt a multi-billion dollar market.

The new Future Mineral UV Defense SPF 50 promises not just protection, but clinically proven anti-aging results and post-procedure care.

A breakthrough drug for pediatric Hunter syndrome, AVLAYAH™, is now accessible via home infusion through an exclusive Orsini and Denali partnership.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.

A new class of ultra-flexible graphene brain implants has safely decoded neural signals in a first-in-human study, heralding a new era for surgery.

A groundbreaking knee implant offers Hoosiers a new joint-preserving option, bridging the gap between conservative care and total knee replacement.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

NAMSA appoints commercial leader Scott Day as VP, signaling a strategic push to expand its end-to-end clinical and consulting services amid industry growth.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

In a crowded market, Zomee's focus on human support, not just tech, earned it a top spot on USA TODAY's first-ever list of most trusted parent brands.